Charles Schwab Investment Management Inc Arcutis Biotherapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 878,804 shares of ARQT stock, worth $11.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
878,804
Previous 859,846
2.2%
Holding current value
$11.4 Million
Previous $8 Million
53.09%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ARQT
# of Institutions
218Shares Held
129MCall Options Held
2.02MPut Options Held
202K-
Jennison Associates LLC12.3MShares$161 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$148 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$143 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$114 Million7.34% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$112 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $784M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...